Glenmark becomes first company to launch Lobeglitazone in India for uncontrolled type 2 diabetes in adults

Glenmark Pharmaceuticals has become the first Pharmaceutical Company to launch Thiazolidinedione Lobeglitazone (Lobeglitazone) in India for the treatment of type 2 diabetes in adults. Marketed under the brand name LOBG; it contains Lobeglitazone (0.5 mg) and to be taken once daily under prescription to improve glycemic control in adult diabetic patients.

glenmark pharmaceuticals arm receives anda approval for solifenacin succinate tablets
Glenmark Pharmaceuticals

Indians have a high prevalence of insulin resistance and that makes LOBG an appealing treatment option in managing uncontrolled Type 2 diabetes among insulin‐resistant diabetic patients

Glenmark earlier received approval from the Indian drug regulator, Drug Controller General of India, for manufacturing and marketing Lobeglitazone based on a randomized, double‐blind Phase 3 clinical trial conducted on adult Type 2 diabetic patients, aged 18 years and older. The results of this trial have shown a faster and improved glycemic control with Lobeglitazone.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.

Download App to read Latest News Today

Leave a Comment